Paclitaxel and Mortality: Where Are We now?

Christopher P Twine*, Hasan H Dosluoglu

*Corresponding author for this work

Research output: Contribution to journalComment/debate (Academic Journal)

2 Downloads (Pure)

Abstract

The high quality adjusted case series by Saratzis et al. 1 puts another strong counter argument to the paclitaxel increases mortality debate started by the meta-analysis from Katsanos et al. in 2018. 2 The reaction to that meta-analysis was unprecedented in recent times, halting international practice despite widespread adoption of the technology and derailing randomised trials.
Original languageEnglish
Number of pages1
JournalEuropean Journal of Vascular and Endovascular Surgery
Early online date4 Apr 2020
DOIs
Publication statusE-pub ahead of print - 4 Apr 2020

Fingerprint Dive into the research topics of 'Paclitaxel and Mortality: Where Are We now?'. Together they form a unique fingerprint.

Cite this